Healthcare
Pfizer Inc.(PFE)
Live Price
Offline$26.17
+2.23% today
1Y Change
+8.36%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $149.77B
- Revenue Growth
- -1.6%
- EPS Growth
- -4.2%
- Dividend Yield
- 6.5%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pfizer Inc. (PFE) is a Healthcare stock with a market cap of $149.77B and listed on NYSE. The stock last traded around $26.17 and up 8.4% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -1.6%, EPS growth of -4.2%, a dividend yield of 6.5%. What stands out right now is revenue -1.6%, EPS -4.2%, free cash flow -7.7% with operating margin 24.7% and ROIC 8.8%. The dividend matters to the case here, with a current yield around 6.5%. Valuation is more restrained than many high-expectation growth names at P/E 19.3 and price/sales 2.4. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines PFE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.6% vs +7.6% peer median
Operating Margin
Above sector median
+24.7% vs +19.4% peer median
P/E
Below sector median
19.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.6% and EPS is at -4.2%, with operating margin around 24.7%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 6.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +0.3% | -2.2% | -4.2% |
2026 Feb 3, 2026 | +16.4% | +3.9% | +7.1% | +3.3% |
2025 Nov 4, 2025 | +37.4% | +1.3% | +5.0% | +5.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PFE
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PFE Max Drawdown
-11.47%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PFE and SPY.
Company Overview
Pfizer Inc.
New York Stock Exchange
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
- Leadership
- Albert Bourla
- IPO Date
- Jun 1, 1972
- Employees
- 81.0k
- Street Address
- 66 Hudson Boulevard East
- Mailing
- New York City, NY, 10001-2192
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 733 2323
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 19.3
- EV/EBITDA
- 12.9
- Price/Sales
- 2.4
- Price/Book
- 1.7
Growth
- Revenue
- -1.6%
- EPS
- -4.2%
- Free Cash Flow
- -7.7%
Profitability
- Gross Margin
- 70.3%
- Operating Margin
- 24.7%
- Net Margin
- 12.4%
- ROE
- 8.7%
- ROIC
- 8.8%
Balance Sheet
- Debt/Equity
- 0.78
- Current Ratio
- 1.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.